Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Over the last 12 months, insiders at Genprex, Inc. have bought $0 and sold $0 worth of Genprex, Inc. stock.
On average, over the past 5 years, insiders at Genprex, Inc. have bought $51,887 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $21,478 was made by VACZY CATHERINE M (EVP GC Chief Strategy Officer) on 2023‑04‑21.
2023-04-21 | EVP GC Chief Strategy Officer | 20,000 0.0426% | $1.07 | $21,478 | -31.68% | |||
2023-04-21 | Chairman, President and CEO | 19,000 0.0398% | $1.05 | $20,045 | -31.68% | |||
2021-04-05 | director | 15,000 0.0313% | $4.15 | $62,250 | -37.14% | |||
2019-09-05 | Chief Executive Officer | 1,800 0.0116% | $0.89 | $1,595 | +158.62% | |||
2018-07-30 | President & COO | 500 0.0038% | $3.40 | $1,700 | -47.75% | |||
2018-03-29 | 10 percent owner | 40,000 0.3625% | $5.00 | $200,000 | -53.19% | |||
2018-03-29 | Chief Executive Officer | 10,000 0.0906% | $5.00 | $50,000 | -53.19% | |||
2018-03-29 | 10 percent owner | 50,000 0.4531% | $5.00 | $250,000 | -53.19% |
ROTH JACK A | 10 percent owner | 1338999 15.738% | $1.01 | 1 | 0 | <0.0001% |
VACZY CATHERINE M | EVP GC Chief Strategy Officer | 265000 3.1147% | $1.01 | 1 | 0 | <0.0001% |
Nance Christy M. | 10 percent owner | 50000 0.5877% | $1.01 | 1 | 0 | <0.0001% |
Varner John Rodney | Chairman, President and CEO | 20800 0.2445% | $1.01 | 3 | 0 | +24.58% |
LONGNECKER BRENT M | director | 15000 0.1763% | $1.01 | 1 | 0 | <0.0001% |
Pham Julien L | President & COO | 500 0.0059% | $1.01 | 1 | 0 | <0.0001% |
Armistice Capital Llc | $291,647.00 | 4.66 | 97,868 | New | +$291,647.00 | <0.01 | |
The Vanguard Group | $45,639.00 | 0.73 | 15,315 | -99.16% | -$5.4M | <0.0001 | |
Geode Capital Management | $35,743.00 | 0.57 | 11,991 | -97.57% | -$1.43M | <0.0001 | |
BlackRock | $33,954.00 | 0.54 | 11,394 | -97.5% | -$1.32M | <0.0001 | |
Tower Research Capital | $8,240.00 | 0.13 | 2,765 | -80.38% | -$33,761.65 | <0.0001 | |
Morgan Stanley | $4,455.00 | 0.07 | 1,495 | -97.49% | -$172,728.84 | <0.0001 | |
Group One Trading | $2,467.00 | 0.04 | 828 | -97.5% | -$96,010.40 | <0.0001 | |
UBS | $1,761.00 | 0.03 | 591 | -98.63% | -$126,711.55 | <0.0001 | |
Bank of America | $1,231.00 | 0.02 | 413 | +108.59% | +$640.84 | <0.0001 | |
Royal Bank of Canada | $0 | 0.01 | 98 | -97.16% | -$0 | <0.0001 | |
Sofos Investments, Inc. | $62.00 | <0.01 | 21 | New | +$62.00 | <0.0001 | |
Wells Fargo | $33.00 | <0.01 | 11 | -97.41% | -$1,242.00 | <0.0001 | |
Advisor Group Holdings Inc | $2.00 | <0.01 | 1 | -100% | -$37,102.00 | <0.0001 | |
Vitalstone Financial Llc | $0 | <0.01 | 10 | -97.5% | -$0 | <0.0001 | |
SignatureFD | $3.00 | <0.01 | 1 | -87.5% | -$21.00 | <0.0001 | |
JPMorgan Chase | $15.00 | <0.01 | 5 | -98.16% | -$798.00 | <0.0001 |